Labcorp launches new test for people with skin cancer

Burlington, n.c.--(business wire)--finding treatment options for skin cancer may become easier with the launch of a new test by labcorp (nyse: lh), a leading global life sciences company. the new test measures lymphocyte-activation gene 3 (lag-3) expression levels by immunohistochemistry (ihc) in tumor tissue. lag-3 is an immune-oncology target with demonstrable clinical benefit in patients with melanoma. the test is available for use in both clinical trials and for the care and treatment of pa
LH Ratings Summary
LH Quant Ranking